Plaintiffs suing over the blood-thinner Xarelto are manipulating the pool of cases set for trial and crowding the docket with claims that should not have been filed, two drug companies have claimed as part of their effort to revamp how the next wave of Xarelto cases should be selected for trial in Philadelphia.
The plaintiffs shot back with a claim that defendants have made misleading statements to the court in hopes of steering the judge to adopt an unfair selection process.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
